ArticleArchives of osteoporosis2016
Patient-reported barriers to osteoporosis therapy.
Article in Archives of osteoporosis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Healthcare professionals' perspectives and experiences of osteoporosis medication treatment: a qualitative systematic review.Archives of osteoporosis · 2024Pooled it
- A systematic review of factors affecting medication adherence among patients with osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018Pooled it
- Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.PharmacoEconomics - open · 2026Article
- Professional positioning of general practitioners in the management of postmenopausal osteoporosis in community medicine.EULAR rheumatology open · 2026Article
- Current practice and barriers in fragility hip fracture management: insights from a national survey of Thai orthopaedic surgeons.BMC health services research · 2026Article
- Living with osteoporosis: a qualitative descriptive study.Archives of osteoporosis · 2025Article
- Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Knowledge gap in a cross section of Irish general practitioners prescribing denosumab for osteoporosis.Irish journal of medical science · 2024Article
- Nutraceuticals in osteoporosis prevention.Frontiers in nutrition · 2024Review
- Effect of Baduanjin exercise on primary osteoporosis: study protocol for randomized controlled trial.BMC complementary medicine and therapies · 2023Article
- Investigating the impact of a national educational program on patient adherence to osteoporosis medications.Archives of osteoporosis · 2023Observational
- Fragility fracture care gap at a tertiary teaching hospital in Malaysia.Archives of osteoporosis · 2023Article
- Characteristics of subsequent contralateral proximal femoral fracture: more convenient access is needed to treat osteoporosis.Journal of orthopaedic surgery and research · 2023Article
- Exploring the osteoporosis treatment gap after fragility hip fracture at a Tertiary University Medical Center in Thailand.BMC geriatrics · 2023Article
- Geriatric fracture program centering age-friendly care associated with lower length of stay and lower direct costs.Health services research · 2023Article
- The clinician's guide to prevention and treatment of osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Understanding Physicians' Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach.Risk management and healthcare policy · 2022Article
- Prevalence of osteoporosis in elderly women in Hong Kong.Osteoporosis and sarcopenia · 2021Article
- Xian-Ling-Gu-Bao protects osteoporosis through promoting osteoblast differentiation by targeting miR-100-5p/KDM6B/RUNX2 axis.In vitro cellular & developmental biology. Animal · 2021Article
- Current practice patterns of osteoporosis treatment in cancer patients and effects of therapeutic interventions in a tertiary center.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated reasons for non-treatment of osteoporosis and discontinuation of osteoporosis therapy. Barriers to treatment include patients' preference for alternative treatments and a fear of possible side effects. Side effects are a common reason for treatment discontinuation, and they may be associated with a lack of willingness to restart treatment. PURPOSE/
introductionOsteoporosis patients commonly cite treatment-related side effects, or the fear thereof, as a reason for discontinuing or not initiating anti-osteoporosis medications. The purpose of this study was to investigate, from the patient's perspective, reasons for (i) non-treatment of osteoporosis and (ii) discontinuation of osteoporosis therapy.
methodsThis was an internet-based survey of postmenopausal women in the USA who self-reported having been diagnosed with osteoporosis. Respondents were recruited from consumer research panels and received nominal compensation.
resultsWithin the surveyed population (N = 1407), 581 patients were currently being treated, 503 had never been treated, and 323 had previously been treated. Among patients never treated for osteoporosis, the highest ranking reasons for non-treatment were the use of alternative treatments such as over-the-counter vitamins/supplements (57.5 % of respondents) and fear of side effects (43.9 %). Among previously treated patients, frequent reasons for discontinuation included the direction of the physician (41.2 % of respondents), concerns about long-term safety (30.3 %), and the experience of side effects (29.8 %). When asked about their willingness to restart their osteoporosis medication, previously treated patients who were not willing (N = 104) to restart had a higher frequency of experiencing side effects (44.2 versus 20.5 % of those willing; P < 0.001).
conclusionsFrom the osteoporosis patient's perspective, barriers to prescription treatment include a preference for alternative, non-prescription treatments and a fear of possible side effects. Side effects are one of the most common reasons for discontinuing osteoporosis medications, and they appear to be associated with a lack of willingness to restart treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.